drugset
drugset / Trial / NCT00003646

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00003646 ↗

Phase 2 Completed 78 enrolled Vical
Open-labelTreatment

Summary

RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.

Timeline

Start
1998-08
Primary completion
2002-03
Completion
2002-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Allovectin-7® Other / unclassified — Other

Indications

melanoma